Aranesp (darbepoetin alfa) Non-oncology

Aranesp is covered only for non‑oncology anemia due to chronic kidney disease in patients on dialysis and in patients not on dialysis (other indications are excluded). Coverage requires documentation of CKD and dialysis status, and for patients not on dialysis adequate iron stores or current iron therapy plus hemoglobin thresholds for initial authorization <10.0 g/dL in adults (≥18) or ≤11.0 g/dL in <18; if already on an ESA, thresholds are <11.5 g/dL in adults or ≤12.0 g/dL in <18, with approvals limited to 12 months.

"Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis."

Sign up to see full coverage criteria, indications, and limitations.